Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 21, 2014; 20(27): 8928-8938
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8928
Molecular biomarkers for the detection of metastatic colorectal cancer cells
Hidenori Kamiyama, Hiroshi Noda, Fumio Konishi, Toshiki Rikiyama
Hidenori Kamiyama, Hiroshi Noda, Fumio Konishi, Toshiki Rikiyama, Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan
Hidenori Kamiyama, Department of Surgery, Chichibu Municipal Hospital, Saitama 368-0025, Japan
Author contributions: Kamiyama H and Noda H contributed to the article design, writing, and revision; Konishi F and Rikiyama T contributed to sample collection and provided advice concerning the study; all authors have approved the version to be published.
Correspondence to: Hiroshi Noda, MD, Department of Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan. noda164@hotmail.co.jp
Telephone: +81-48-6472111 Fax: +81-48-6485188
Received: September 27, 2013
Revised: January 29, 2014
Accepted: April 1, 2014
Published online: July 21, 2014
Core Tip

Core tip: We focus on methods of the detection of molecular changes in metastatic colorectal cancer cells, and describe the characteristics for the methods, such as DNA methylation, mRNA, microRNA, immunomagnetic separation, protein and cancer-associated mutations. Moreover, we review the clinical significance according to the type of samples, such as blood, lymph node, bone marrow and peritoneal lavage fluid. At present, it is difficult to conclude that one specific molecular marker is superior to others. Comparative analyses are recommended to assess the prognostic impact of molecular analyses in the same patient and determine the biomarkers that provide the most accurate prognostic information.